BACKGROUND: A synergistic effect resulting from a combination of BCL2 and MYC or MYC and CCND1 has been implicated in human B-cell lymphomas. Although the identification of other cooperative genes involved is important, our present understanding of such genes remains scant. The objective of this study was to identify the additional cooperative gene(s) associated with BCL2 and MYC or MYC and CCND1. First, we assessed whether Bcl2, Myc and Ccnd1 could cooperate. Next, we developed a synergism-based functional screening method for the identification of other oncogene(s) that act with Bcl2 and Myc. DESIGN AND METHODS: Growth in culture, colony formation and oncogenicity in vivo were assessed in mouse primary B cells exogenously expressing various combinations of Bcl2, Myc and Ccnd1. For the functional screening, Bcl2- and Myc-expressing primary B cells were infected with a retroviral cDNA library. Inserted cDNA of transformed cells in culture were then identified. RESULTS: Primary B cells exogenously expressing Bcl2, Myc and Ccnd1 showed factor-independent growth ability, enhanced colony-forming capability and aggressive oncogenicity, unlike the cases observed with the expression of any combination of only two of the genes. We identified CCND3 and NRAS as cooperative genes with Bcl2 and Myc through the functional screening. CONCLUSIONS: Bcl2, Myc and Ccnd1 or Bcl2, Myc and CCND3 synergistically transformed mouse primary B cells into aggressive malignant cells. Our new synergism-based method is useful for the identification of synergistic gene combinations in tumor development, and may expand our systemic understanding of a wide range of cancer-causing elements.
BACKGROUND: A synergistic effect resulting from a combination of BCL2 and MYC or MYC and CCND1 has been implicated in human B-cell lymphomas. Although the identification of other cooperative genes involved is important, our present understanding of such genes remains scant. The objective of this study was to identify the additional cooperative gene(s) associated with BCL2 and MYC or MYC and CCND1. First, we assessed whether Bcl2, Myc and Ccnd1 could cooperate. Next, we developed a synergism-based functional screening method for the identification of other oncogene(s) that act with Bcl2 and Myc. DESIGN AND METHODS: Growth in culture, colony formation and oncogenicity in vivo were assessed in mouse primary B cells exogenously expressing various combinations of Bcl2, Myc and Ccnd1. For the functional screening, Bcl2- and Myc-expressing primary B cells were infected with a retroviral cDNA library. Inserted cDNA of transformed cells in culture were then identified. RESULTS: Primary B cells exogenously expressing Bcl2, Myc and Ccnd1 showed factor-independent growth ability, enhanced colony-forming capability and aggressive oncogenicity, unlike the cases observed with the expression of any combination of only two of the genes. We identified CCND3 and NRAS as cooperative genes with Bcl2 and Myc through the functional screening. CONCLUSIONS:Bcl2, Myc and Ccnd1 or Bcl2, Myc and CCND3 synergistically transformed mouse primary B cells into aggressive malignant cells. Our new synergism-based method is useful for the identification of synergistic gene combinations in tumor development, and may expand our systemic understanding of a wide range of cancer-causing elements.
Authors: Andreas Rosenwald; George Wright; Adrian Wiestner; Wing C Chan; Joseph M Connors; Elias Campo; Randy D Gascoyne; Thomas M Grogan; H Konrad Muller-Hermelink; Erlend B Smeland; Michael Chiorazzi; Jena M Giltnane; Elaine M Hurt; Hong Zhao; Lauren Averett; Sarah Henrickson; Liming Yang; John Powell; Wyndham H Wilson; Elaine S Jaffe; Richard Simon; Richard D Klausner; Emilio Montserrat; Francesc Bosch; Timothy C Greiner; Dennis D Weisenburger; Warren G Sanger; Bhavana J Dave; James C Lynch; Julie Vose; James O Armitage; Richard I Fisher; Thomas P Miller; Michael LeBlanc; German Ott; Stein Kvaloy; Harald Holte; Jan Delabie; Louis M Staudt Journal: Cancer Cell Date: 2003-02 Impact factor: 31.743
Authors: T Sonoki; L Harder; D E Horsman; L Karran; I Taniguchi; T G Willis; S Gesk; D Steinemann; E Zucca; B Schlegelberger; F Solé; A J Mungall; R D Gascoyne; R Siebert; M J Dyer Journal: Blood Date: 2001-11-01 Impact factor: 22.113
Authors: Martin Filipits; Ulrich Jaeger; Gudrun Pohl; Thomas Stranzl; Ingrid Simonitsch; Alexandra Kaider; Cathrin Skrabs; Robert Pirker Journal: Clin Cancer Res Date: 2002-03 Impact factor: 12.531
Authors: Maria A Ciemerych; Anna M Kenney; Ewa Sicinska; Ilona Kalaszczynska; Roderick T Bronson; David H Rowitch; Humphrey Gardner; Piotr Sicinski Journal: Genes Dev Date: 2002-12-15 Impact factor: 11.361
Authors: Bhavna S Paratala; Jon H Chung; Casey B Williams; Bahar Yilmazel; Whitney Petrosky; Kirstin Williams; Alexa B Schrock; Laurie M Gay; Ellen Lee; Sonia C Dolfi; Kien Pham; Stephanie Lin; Ming Yao; Atul Kulkarni; Frances DiClemente; Chen Liu; Lorna Rodriguez-Rodriguez; Shridar Ganesan; Jeffrey S Ross; Siraj M Ali; Brian Leyland-Jones; Kim M Hirshfield Journal: Nat Commun Date: 2018-11-16 Impact factor: 14.919